Expert Interview
An overview of next generation "oral biologics" in treating inflammatory/rheumatological disease
Ticker(s): IBB, ACRS, DICE, VTYX, IMUX, KYMR, BMY, PTGX, PFEInstitution: Rheumatology Therapeutics Medical Center
- Rheumatologist at RTMC & Staff Physician at Cedar-Sinai Providence Tarzana Medical Center; fellowship trained at USC.
- Currently manages 500 patients with Rheumatoid Arthritis.
- Board Certified in both Rheumatology & Internal Medicine; Clinical focus on Rheumatoid Arthritis, Osteoarthritis, Spondyloarthropathies, Lupus, Scleroderma, Mixed Connective Tissue Disease, Sarcoidosis, Osteoporosis, Gout, Inflammatory Myopathies, and Vasculitis.
Could you describe the theoretical differences and the similarities between the different modalities of next generation oral anti inflammatory drugs? (TYK2i, S1Pi, MK2i, IRAK4i, PDE4i, IL-17i etc).
Could you describe which of the drugs are likely to work in what diseases, and why, based on mechanism of action, preclinical data, and existing trials? (TYK2i, S1Pi, MK2i, IRAK4i, PDE4i, IL-17i etc).
What mechanism of action holds the most promise? Why? (TYK2i, S1Pi, MK2i, IRAK4i, PDE4i, IL-17i etc).
Any other targets or MOA that are interesting and in the pipeline?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
